Company: ACTG
Filing Date: 2025-03-17
Form Type: 10-K
Source: 0000934549-25-000004
Chunk: 159

Company: ACACIA RESEARCH CORP
Filing Date: 2025-03-17
Form: 10-K
Item: Item 8
Chunk 159
---
506)Cash flows from investing activities:Acquisition, net of cash acquired (Note 3)(87,678)(9,409)Cash reinvested— 9,965 Patent acquisition(14,000)(6,000)Purchases of equity securities(20,472)(13,072)Sales of equity securities57,854 32,106 Distributions received from equity investment in joint venture— 2,777 Net purchases of property and equipment and additions to oil and gas properties(148,667)(189)Net cash (used in) provided by investing activities(212,963)16,178 Cash flows from financing activities:Repurchase of common stock(20,288)— Paydown of Senior Secured Notes— (60,000)Contributions from noncontrolling interest15,250 — Borrowings on the Revolving credit facility86,010 — Paydown of Revolving Credit Facility(30,035)(7,700)Borrowings on the Term Loan47,488 — Dividend on Series A Redeemable Convertible Preferred Stock— (1,400)Taxes paid related to net share settlement of share-based awards(1,092)(614)Proceeds from Rights Offering— 79,111 Proceeds from exercise of Series B warrants— 49,000 Proceeds from exercise of stock options223 235 Net cash provided by financing activities97,556 58,632 Effect of exchange rates on cash and cash equivalents(926)1 (Decrease) increase in cash and cash equivalents(66,211)52,305 Cash and cash equivalents, beginning340,091 287,786 Cash and cash equivalents, ending$273,880 $340,091 Supplemental schedule of cash flow information:Interest paid$5,058 $2,513 Income taxes paid1,048 831 Noncash investing and financing activities:Accrued patent costs— 4,000 Distribution to noncontrolling interests in subsidiaries— 1,390 

The accompanying notes are an integral part of these consolidated financial statements 

F-6